A randomized clinical trial finds that continuous glucose monitors (CGMs) improve blood sugar control in adults with type 2 diabetes who are not using insulin. The reporting from PR Newswire and MedPage Today says the study shows meaningful changes in measures of glucose levels, including time spent in healthy ranges, and improvements in HbA1c.
Both outlets describe the CONNECT trial, carried out across primary care settings, involving 283 participants. PR Newswire emphasizes that CGM use helps patients spend more time each day within target glucose ranges. MedPage Today focuses on the biochemical outcome, reporting that CGM use lowers HbA1c in the insulin-free type 2 diabetes group.
While the outlets highlight different primary endpoints—daily time in range versus HbA1c—they agree on the overall conclusion: CGMs are beneficial for glycemic control in people with type 2 diabetes not treated with insulin, based on randomized trial results.
